Universe Pharmaceuticals INCUPC
Price$4.30

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $17.9B+77,464.2% YoYTTM through 30 Sep 2025
Net Income -$3.7BTTM through 30 Sep 2025
Free Cash Flow -$5.3BTTM through 30 Sep 2025

Margins

Current
Gross Margin35.3%
EBITDA Margin-13.4%
Operating Margin-16.3%
Net Margin-20.6%

Returns

-7.2%ROE
-5.3%ROA

Balance Sheet Health

Debt / Equity0.17x
Current Ratio4.07x
Net Debt-$24.3Mnet cash position
Cash & Equivalents$33.6B

Quality Metrics

Altman Z-Score0.54
Piotroski F-Score3 / 9
FCF Margin-29.8%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $17.9B
Diluted EPS-$8.06TTM
'20'21'22'23'24'25
FY2025: $-8,055.00

Dividend

No dividend

Capital Allocation

R&D Spend$671.8M
Capex Intensity1.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.